WCN25-3638 Steroid avoidance with low-dose tacrolimus is safe and effective for kidney transplant recipients with low immunologic risk in the long-term: SAILOR II follow-up study

respectively (p0.426).Death-censored graft survival at 1-, 3-, 5-, and 10-years were 98.2%,93.2%,88.1%,and 66.6% for HLA-sensitized and 98.6%,96.9%,94.7%,and 85.3% for non-sensitized patients (p0.161),respectively.Poor graft outcome was identified as a significant predictor of mortality (HR4.80,p0.002).Serious infections requiring hospitalization (SIRH) within the first year occurred in 31.5% of sensitized patients and 44.4% of non-sensitized patients (p0.080), while post-1-year infections occurred in 27.1% of sensitized patients and 36.9% of non-sensitized patients (p0.181).Conclusions: HLA sensitization in ABO-i KT does not significantly impact graft survival or overall mortality compared to non-sensitized patients.However, early infectious complications were similar.This study underscores the feasibility and safety of ABO-i KT in sensitized patients, expanding the donor pool and improving access to transplantation for high-risk groups, and provides insights for optimizing transplant protocols in similar settings.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.